While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
But mixed data and a previous failure provide reasons to be cautious.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Novo moves into amyloidosis not long after Intellia made a splash here.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.